" class="no-js "lang="en-US"> Daewoong Begins New Treatment for Idiopathic Pulmonary Fibrosis
Saturday, April 01, 2023

Daewoong Pharmaceutical Begins the First Administration of the Bersiporocin, a New Treatment for Idiopathic Pulmonary Fibrosis

The world’s first-in-class candidate substance against idiopathic pulmonary fibrosis, ‘Bersiposocin‘ (DWN12088), which is under the development of Daewoong Pharmaceutical, has entered its Phase II clinical administration.

Daewoong Pharmaceutical has announced that the first patient has been administrated in Phase II on the 6th. The Bersiporocin’s multinational Phase II has been performed by approx. 30 institutions in Korea and US. A total of 102 patients are evaluated for the safety of Bersiporocin and the efficacy of changes in the improvement rate of FVC(forced vital capacity) after administering the Bersiporocin or placebo for 24 weeks. They are aiming to complete the administration to the subjects and check the results by 2024.

Daewoong Pharmaceutical is planning to prove Bersiporocin’s excellent antifibrotic efficacy and pulmonary function improvement results with the oncoming multinational Phase II clinical administration, which has been confirmed from the last non-clinical test. If Daewoong Pharmaceutical succeeds in Bersiporocin’s Proof of Concept, it will be probable for the extended adaptability against various rare fibrosis diseases as well as the export of technology.

The main disease which Bersiporocin is effective against is idiopathic pulmonary fibrosis, which is a lung disease caused by overly formed fibrous tissue hardening the lungs, resulting in the lungs to lose their function. It is a known rare and complicated disease with a 5-year survival rate of less than 40% after diagnosis, as it is challenging to treat. The current treatment for idiopathic pulmonary fibrosis in the market by multinational pharmaceutical companies cannot completely stop the process of the disease and has a high rate of giving up on the administration due to side effects, so the medical demand for such treatment is still high.

“We are working hard to develop a new treatment for patients with idiopathic pulmonary fibrosis.” said the chair of the Trial steering committee, Toby Maher, M.D., Ph.D., Professor of Clinical Medicine, Keck School of Medicine, USC Los Angeles. “The Phase II clinical trial of Daewoong Pharmaceutical’s Bersiposocin represents an important step in developing treatments that address the shortcomings of existing anti fibrotic therapies.”

According to the global market research institution Research And Markets, the global market of idiopathic pulmonary fibrosis treatment is growing by 7% each year, and anticipated to reach approx. 6.1 billion dollars (approx. 8 trillion won) by 2030. Daewoong Pharmaceutical will continue to make efforts on developing highly-demanded treatment for the fibroid lung patients, as well as extending the target to other progressive rare fibrosis diseases of the lung, skin, kidney, liver, and heart.

Companies In This Post

  1. Insmed Completes Enrollment of Adult Patients in Phase 3 ASPEN Study of Brensocatib in Bronchiectasis Read more
  2. NEC Establishes Subsidiaries in Europe for Strengthening Global AI Drug Development Business Read more
  3. Flare Therapeutics Further Strengthens Leadership Team with Key Executive Appointments and Promotions Read more
  4. Sensorion Appoints Khalil Barrage as Interim Chairman of the Board Read more
  5. Ablaze Pharmaceuticals Plans Development of Innovative GPC3 Targeted Radiopharmaceutical Therapy for Liver Cancer in Greater China Read more